Plain-English translation of NCT06522919 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating advanced colorectal cancer that has stopped responding to standard treatments. The study combines three elements: a personalized vaccine made from your own immune cells, an immunotherapy drug called pembrolizumab, and then a chemotherapy combination. The goal is to see if this sequential approach can slow or stop cancer growth better than chemotherapy alone.
Advanced colorectal cancer with certain genetic features (like yours) doesn't respond well to standard immunotherapy treatments used for other types of colorectal cancer. Recent research shows that combining immunotherapy with chemotherapy, and then using a personalized vaccine to prime the immune system, might help the chemotherapy work better. This trial is testing whether this new sequence of treatments can improve survival.
You likely qualify if…
You likely don't qualify if…
First, you'll undergo leukapheresis (a procedure to collect your immune cells, which are sent to the lab to create your personalized vaccine). Then you'll enter a 9-week induction phase where you receive weekly vaccine injections for 4 weeks, then one more injection 3 weeks later, alongside immunotherapy infusions every 3 weeks. After that, you'll move to the maintenance phase and receive ongoing chemotherapy with a blood vessel-targeting drug until your cancer progresses, you experience unacceptable side effects, or you choose to stop. Throughout the trial, you'll have regular blood tests and imaging scans to monitor how well the treatment is working.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Italy